Since then, the approval of additional agents such as next generation AR signaling inhibitors (ARSi) (abiraterone [7], enzalutamide [8], apalutamide [9], darolutamide [10]), chemotherapies (docetaxel [11], cabazitaxel [12]), Radium 223 [13] and Sipuleucel-T [14] have contributed to improved outcomes in advanced PCa. The gene discussed is AR; the disease is posterior cortical atrophy.